Welcome to our CDC Ex Vivo Immuno-oncology Co-culture Platform. This platform is specially designed for research into complement-dependent cytotoxicity, offering cutting-edge solutions for the quantitative analysis of complement-dependent toxicity induced by monoclonal antibodies.

Target Cell Selection:
• We offer a variety of choices including tumor cell lines, primary tumor cells, and genetically engineered cell strains to meet your diverse research needs.

Effector Cell Provision:
• Depending on your experimental needs, we support the use of commercially sourced PBMCs, and also provide PBMCs derived from clinical patients. Our team will recommend the most suitable effector cell group for your specific drug development requirements.

Analysis and Detection:
• We employ flow cytometry techniques, which effectively differentiate between effector and target cells, providing precise counts and calculating apoptotic cell proportions to offer accurate and reliable data support.
• Additionally, to give a more comprehensive assessment of the experimental outcomes, we also utilize the LDH method to detect the activity of tumor cells.

Validate the in vitro CDC activity of Rituximab on Raji cells.